All News
RA really does still impact employment outcomes for many, despite T2T.
@earlyarthritis🇨🇦 data in working age people show many back in the game in the first year, but not many more after that.
Plenty more to do to get all our pts back to their best!
ABST1967 #ACR22 @RheumNow https://t.co/isD1rgkFoH
David Liew drdavidliew ( View Tweet)
SURPASS was a head-to-head study comparing SEC vs ADA biosimilar (SDZ-ADL) in r-axSpA on spinal radio progression:
Results showed no significant diff in spinal radio progression bet. the 2 grps.
Biosimilars remain tx options for r-axSpA.
#ACR22 @RheumNow ABST#L15
sheila RHEUMarampa ( View Tweet)
Foot involvement in RA not included in disease activity scores. This abstract showed that patients w/ active foot involvement have higher scores anyway (driven by physician & patient global) but examining feet would have only changed management in 3.1%.
@RheumNow ABST0265 #ACR22 https://t.co/ckuB8R4ZTF
Julian Segan JulianSegan ( View Tweet)
Response to ULT
in
Hyperuricaemia +non episodic foot pain not meeting criteria for gout classification predicted by
🔥US findings of
👉double contour sign
👉tophus
Abst 1828 #ACR22 @FloodRachael @RheumNow https://t.co/ATzEgFOWU0
Patricia Harkins DrTrishHarkins ( View Tweet)
PNEUMOVAS study results suggest AAV pts on RTX showed improved S. Pneumoniae ab response with double dose of PCV13 at day 0 and day 7 followed by a single dose of PPV23 at M5. More data needed on this updated, clinical strategy. Abs L16 #ACR22 @RheumNow https://t.co/m71VQMGZ68
Dr. Rachel Tate uptoTate ( View Tweet)
Polymyalgia rheumatica: more than just steroids at #ACR22
After decades of having little else proven apart from glucocorticosteroids with which to treat PMR, evidence for steroid-sparing options has grown in recent years.
https://t.co/CjMzEqRan8 https://t.co/5UixhVemqY
Links:
Dr. John Cush RheumNow ( View Tweet)
SMS/email reminders slightly improve fluvax uptake in RA pts
(nested RCT within ART registry, France)
ABST2002 #ACR22 @RheumNow
@philipcrobinson & I wrote @TheLancetRheum on how to improve preventative med https://t.co/55j8rdv3nV
I think we need multiple simultaneous strategies! https://t.co/pNfpWLVkac
David Liew drdavidliew ( View Tweet)
Big change for #SLE Trials coming soon.
My exclusive interview w/Prof @EricFMorand. Future trials will likely incorporate this Novel Treatment Response Measurement (TRM) Tool #ACR22 @rheumnow https://t.co/TXsxJi3qhC
TheDaoIndex KDAO2011 ( View Tweet)
Our work presented at #ACR22 showing increased mast cells and tryptase activity in women with OA compared to men!
Food for thought - can simple allergy meds help in OA management?
@RheumNow abst#1642. https://t.co/cBQZU5MXeR
Bella Mehta bella_mehta ( View Tweet)
Cancer risk with tofacitinib vs TNFi in RA:
we learned at #ACR21 that
CV-enriched pts: risk (ORAL Surveillance)
all comers: no risk (STAR-RA)
French national healthcare database #ACR22 looks at all comers: nothing to separate tofa and TNFi.
Risk begets risk
ABST1984 @RheumNow https://t.co/0GG04NSP3D https://t.co/nwQz7fx21M
David Liew drdavidliew ( View Tweet)
Based on your experience, will you attend #ACR23 next year ... @ACRheum @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
⚡️Pulmonary pulse wave transit time⚡️
👉novel non-invasive echo measure of ⬆️pulm vasc tone in pulm HTN
👉hyperuricaemic pts ⬇️pPTT sugg of pulm vasc dysfn
@FloodRachael #ACR22 Abst1788 @RheumNow https://t.co/ZEORWbqw6f
Patricia Harkins DrTrishHarkins ( View Tweet)
Still for me the most interesting bit from the GLORIA study (PNL 5 add-on in RA) is the coming off of it.
Patients were able to come off their long-term low-dose prednisolone. No Sx/biochem differences vs placebo.
True #squadgoals for rheumatologists
ABST2000 #ACR22 @RheumNow https://t.co/eQLcgqA1SN https://t.co/RGTCrMhld7
David Liew drdavidliew ( View Tweet)
Cumulative dose and exposure to methotrexate were not predictors of hepatic fibrosis.
Hepatic fibrosis as measured by elastography associated with daily EtOH use.
#ACRBest Abs#2147 @RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
Peritonitis of the #FMF - misdiagnosed as acute abdomen
Acute appendicitis is the leading cause of acute abdomen in FMF
Turkish study 1655 #FMF pts
15.8% appendectomy rates!
CRP ineffective for differing FMF from appendicitis :(
@RheumNow #ACR22 abst#1839
Bella Mehta bella_mehta ( View Tweet)
Factors associated with non-achievement of MDA in PsA pts receiving golimumab:
Baseline tender joint count, fibromyalgia, older age, smoking, high BMI
Abs#2109 @RheumNow #ACR22 https://t.co/dEzQxVtavh
Robert B Chao, MD doctorRBC ( View Tweet)
‼️‼️Frailty ‼️‼️
👉Important predictor of serious infxn in RA pts on b- or tsDMARD irrespective of age ‼️‼️
@NamrataRheum illustrating yet another reason why it is so NB to evaluate 4 frailty in ALL (incl young) pts with RA
#GeriRheum
Abst2218 @RheumNow #ACR22 https://t.co/J4XQFmVoUw
Patricia Harkins DrTrishHarkins ( View Tweet)
While there are limitations to this study (respondents over childbearing age, white, educated, insured), within 2 months of @USSupremeCourt3's overturn of Roe v Wade, 1 in 17 MTX pts experienced a barrier to getting rx filled. ABS L09 @RheumNow #ACR22 https://t.co/WuikwO1bZ9 https://t.co/4Ve0zAVxbG
Dr. Rachel Tate uptoTate ( View Tweet)
Early psoriasis and enthesitis response in PsA pts treated with guselkumab predicted longterm clinical response including MDA, DAPSA LDA, DAPSA50, DAPSA remission.
Pts w/o early response, only half achieved remission
Abs#2115 @RheumNow #ACR22 https://t.co/dnsQcp7cEq
Robert B Chao, MD doctorRBC ( View Tweet)
BKZ showed clinically meaningful improvements in efficacy outcomes in bDMARD-naïve PsA pts at Wk 16 through wk 52. No new safety signals. ABS L02 #ACR22 @RheumNow https://t.co/Dph32O7NWG https://t.co/d7Yq3JISyF
Dr. Rachel Tate uptoTate ( View Tweet)